S&P 500   3,392.50 (-0.25%)
DOW   27,479.41 (-0.74%)
QQQ   283.07 (+0.93%)
AAPL   116.72 (+1.45%)
MSFT   214.45 (+2.08%)
FB   283.89 (+2.45%)
GOOGL   1,598.75 (+0.91%)
AMZN   3,284.00 (+2.40%)
TSLA   424.55 (+1.02%)
NVDA   536.46 (+2.06%)
BABA   318.89 (+3.92%)
CGC   18.72 (+1.03%)
GE   7.13 (-3.39%)
MU   52.16 (+0.04%)
AMD   78.89 (-4.06%)
T   26.99 (-1.42%)
F   7.94 (-1.12%)
ACB   4.01 (-8.86%)
GILD   60.06 (+0.17%)
NFLX   488.30 (+0.01%)
NIO   28.29 (+8.77%)
BA   156.11 (-2.93%)
DIS   123.29 (-0.62%)
S&P 500   3,392.50 (-0.25%)
DOW   27,479.41 (-0.74%)
QQQ   283.07 (+0.93%)
AAPL   116.72 (+1.45%)
MSFT   214.45 (+2.08%)
FB   283.89 (+2.45%)
GOOGL   1,598.75 (+0.91%)
AMZN   3,284.00 (+2.40%)
TSLA   424.55 (+1.02%)
NVDA   536.46 (+2.06%)
BABA   318.89 (+3.92%)
CGC   18.72 (+1.03%)
GE   7.13 (-3.39%)
MU   52.16 (+0.04%)
AMD   78.89 (-4.06%)
T   26.99 (-1.42%)
F   7.94 (-1.12%)
ACB   4.01 (-8.86%)
GILD   60.06 (+0.17%)
NFLX   488.30 (+0.01%)
NIO   28.29 (+8.77%)
BA   156.11 (-2.93%)
DIS   123.29 (-0.62%)
S&P 500   3,392.50 (-0.25%)
DOW   27,479.41 (-0.74%)
QQQ   283.07 (+0.93%)
AAPL   116.72 (+1.45%)
MSFT   214.45 (+2.08%)
FB   283.89 (+2.45%)
GOOGL   1,598.75 (+0.91%)
AMZN   3,284.00 (+2.40%)
TSLA   424.55 (+1.02%)
NVDA   536.46 (+2.06%)
BABA   318.89 (+3.92%)
CGC   18.72 (+1.03%)
GE   7.13 (-3.39%)
MU   52.16 (+0.04%)
AMD   78.89 (-4.06%)
T   26.99 (-1.42%)
F   7.94 (-1.12%)
ACB   4.01 (-8.86%)
GILD   60.06 (+0.17%)
NFLX   488.30 (+0.01%)
NIO   28.29 (+8.77%)
BA   156.11 (-2.93%)
DIS   123.29 (-0.62%)
S&P 500   3,392.50 (-0.25%)
DOW   27,479.41 (-0.74%)
QQQ   283.07 (+0.93%)
AAPL   116.72 (+1.45%)
MSFT   214.45 (+2.08%)
FB   283.89 (+2.45%)
GOOGL   1,598.75 (+0.91%)
AMZN   3,284.00 (+2.40%)
TSLA   424.55 (+1.02%)
NVDA   536.46 (+2.06%)
BABA   318.89 (+3.92%)
CGC   18.72 (+1.03%)
GE   7.13 (-3.39%)
MU   52.16 (+0.04%)
AMD   78.89 (-4.06%)
T   26.99 (-1.42%)
F   7.94 (-1.12%)
ACB   4.01 (-8.86%)
GILD   60.06 (+0.17%)
NFLX   488.30 (+0.01%)
NIO   28.29 (+8.77%)
BA   156.11 (-2.93%)
DIS   123.29 (-0.62%)
Log in
NYSE:ABBV

AbbVie Stock Forecast, Price & News

$83.13
-0.79 (-0.94 %)
(As of 10/27/2020 03:39 PM ET)
Add
Compare
Today's Range
$83.11
Now: $83.13
$85.00
50-Day Range
$82.89
MA: $87.60
$91.87
52-Week Range
$62.55
Now: $83.13
$101.28
Volume382,873 shs
Average Volume6.92 million shs
Market Capitalization$146.71 billion
P/E Ratio17.69
Dividend Yield5.60%
Beta0.74
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; I-Mab; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Read More
AbbVie logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.3Community Rank: 2.9Dividend Strength: 3.3Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

2.69 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
CUSIP00287Y10
Phone847-932-7900
Employees30,000

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$33.27 billion
Cash Flow$10.19 per share
Book Value($5.53) per share

Profitability

Net Income$7.88 billion

Miscellaneous

Outstanding Shares1,764,830,000
Market Cap$146.71 billion
Next Earnings Date10/30/2020 (Confirmed)
OptionableOptionable
$83.13
-0.79 (-0.94 %)
(As of 10/27/2020 03:39 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ABBV News and Ratings via Email

Sign-up to receive the latest news and ratings for ABBV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











AbbVie (NYSE:ABBV) Frequently Asked Questions

How has AbbVie's stock price been impacted by Coronavirus (COVID-19)?

AbbVie's stock was trading at $84.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, ABBV shares have decreased by 1.8% and is now trading at $83.29.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of AbbVie?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AbbVie in the last year. There are currently 1 sell rating, 4 hold ratings and 14 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for AbbVie
.

When is AbbVie's next earnings date?

AbbVie is scheduled to release its next quarterly earnings announcement on Friday, October 30th 2020.
View our earnings forecast for AbbVie
.

How can I listen to AbbVie's earnings call?

AbbVie will be holding an earnings conference call on Friday, October 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) announced its quarterly earnings data on Friday, July, 31st. The company reported $2.34 earnings per share for the quarter, topping the Zacks' consensus estimate of $2.20 by $0.14. The firm earned $10.43 billion during the quarter, compared to analysts' expectations of $10.14 billion. AbbVie had a negative return on equity of 628.57% and a net margin of 19.20%. The firm's revenue for the quarter was up 26.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.26 earnings per share.
View AbbVie's earnings history
.

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie announced a quarterly dividend on Friday, September 11th. Investors of record on Thursday, October 15th will be given a dividend of $1.18 per share on Monday, November 16th. This represents a $4.72 dividend on an annualized basis and a dividend yield of 5.67%. The ex-dividend date of this dividend is Wednesday, October 14th.
View AbbVie's dividend history
.

How will AbbVie's stock buyback program work?

AbbVie announced that its Board of Directors has approved a stock repurchase plan on Thursday, December 13th 2018, which allows the company to repurchase $5,000,000,000.00 in shares, according to EventVestor. This repurchase authorization allows the company to reacquire up to 3.8% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company's management believes its stock is undervalued.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY20 earnings guidance on Friday, July, 31st. The company provided earnings per share (EPS) guidance of $10.35-10.45 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $10.51.

What price target have analysts set for ABBV?

19 brokerages have issued 1 year target prices for AbbVie's stock. Their forecasts range from $90.00 to $127.00. On average, they expect AbbVie's stock price to reach $108.71 in the next twelve months. This suggests a possible upside of 30.5% from the stock's current price.
View analysts' price targets for AbbVie
.

Who are some of AbbVie's key competitors?

What other stocks do shareholders of AbbVie own?

Who are AbbVie's key executives?

AbbVie's management team includes the following people:
  • Mr. Richard A. Gonzalez, Chairman & CEO (Age 66, Pay $7.11M)
  • Dr. Michael E. Severino, Vice Chairman & Pres (Age 54, Pay $3.98M)
  • Mr. Robert A. Michael, Exec. VP & CFO (Age 50, Pay $2.76M)
  • Ms. Laura J. Schumacher, Vice Chairman of External Affairs, Chief Legal Officer & Corp. Sec. (Age 57, Pay $4.3M)
  • Mr. Carlos Alban, Vice Chairman & Chief Commercial Officer (Age 57, Pay $4.08M)

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

Who are AbbVie's major shareholders?

AbbVie's stock is owned by a number of institutional and retail investors. Top institutional investors include Standard Life Aberdeen plc (0.23%), LSV Asset Management (0.21%), Envestnet Asset Management Inc. (0.13%), Retirement Systems of Alabama (0.09%), PGGM Investments (0.09%) and State of New Jersey Common Pension Fund D (0.07%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Brian L Durkin, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Richard A Gonzalez, Roxanne S Austin, Timothy J Richmond and William J Chase.
View institutional ownership trends for AbbVie
.

Which institutional investors are selling AbbVie stock?

ABBV stock was sold by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Standard Life Aberdeen plc, 10 15 Associates Inc., Retirement Systems of Alabama, Pacer Advisors Inc., Redpoint Investment Management Pty Ltd, MAI Capital Management, and LSV Asset Management. Company insiders that have sold AbbVie company stock in the last year include Carlos Alban, Jeffrey Ryan Stewart, and Timothy J Richmond.
View insider buying and selling activity for AbbVie
.

Which institutional investors are buying AbbVie stock?

ABBV stock was purchased by a variety of institutional investors in the last quarter, including PGGM Investments, Assenagon Asset Management S.A., Hamlin Capital Management LLC, Bradley Foster & Sargent Inc. CT, Foundry Partners LLC, Ferguson Wellman Capital Management Inc., Avantax Advisory Services Inc., and Garland Capital Management Inc.. Company insiders that have bought AbbVie stock in the last two years include Brian L Durkin, Edward J Rapp, Henry O Gosebruch, Istar Inc, Jeffrey Ryan Stewart, Laura J Schumacher, Nicholas Donoghoe, Roxanne S Austin, and William J Chase.
View insider buying and selling activity for AbbVie
.

How do I buy shares of AbbVie?

Shares of ABBV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is AbbVie's stock price today?

One share of ABBV stock can currently be purchased for approximately $83.29.

How big of a company is AbbVie?

AbbVie has a market capitalization of $146.99 billion and generates $33.27 billion in revenue each year. The company earns $7.88 billion in net income (profit) each year or $8.94 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

What is AbbVie's official website?

The official website for AbbVie is www.abbvie.com.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.

This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.